C4 Therapeutics, Inc.

NasdaqGS:CCCC Aktierapport

Börsvärde: US$395.8m

C4 Therapeutics Förvaltning

Förvaltning kriterier kontrolleras 4/4

C4 Therapeutics VD är Andrew Hirsch, utsedd i Sep 2020, har en mandatperiod på 5.75 år. totala årliga ersättningen är $ 2.94M, bestående av 23.6% lön 76.4% bonusar, inklusive företagsaktier och optioner. äger direkt 0.12% av företagets aktier, värda $ 485.76K. Den genomsnittliga mandatperioden för ledningsgruppen och styrelsen är 5.4 år respektive 7.8 år.

Viktig information

Andrew Hirsch

Verkställande direktör

US$2.9m

Total ersättning

VD-lön i procent23.63%
Anställning som VD5.8yrs
Ägande av VD0.1%
Ledningens genomsnittliga anställningstid5.4yrs
Styrelsens genomsnittliga mandatperiod7.8yrs

Senaste uppdateringar av ledningen

Recent updates

Seeking Alpha • Jun 02

C4 Therapeutics "Buy" On Cemsidomide Advancement And Competitor's Positive Readout

Summary I initiate C4 Therapeutics (CCCC) with a "Buy rating," driven by robust progress of its next-gen CELMoD cemsidomide in relapsed/refractory multiple myeloma. Company's lead program advances through phase 2 MOMENTUM and phase 1b combination studies, with key data catalysts expected at EHA 2026 and throughout 2026–2027. Strong financial position with $268.3M cash as of March 2026 supports operations into 2028, enabling continued pipeline expansion and clinical execution. Validation from Bristol-Myers’ phase 3 mezigdomide data underscores the foundational role of IKZF1/3 degraders, supporting CCCC’s strategic direction and potential best-in-class ambitions. Read the full article on Seeking Alpha
Analysartikel • May 15

C4 Therapeutics, Inc. (NASDAQ:CCCC) Just Reported And Analysts Have Been Lifting Their Price Targets

C4 Therapeutics, Inc. ( NASDAQ:CCCC ) defied analyst predictions to release its quarterly results, which were ahead of...
Analysartikel • Dec 17

Insufficient Growth At C4 Therapeutics, Inc. (NASDAQ:CCCC) Hampers Share Price

You may think that with a price-to-sales (or "P/S") ratio of 7.3x C4 Therapeutics, Inc. ( NASDAQ:CCCC ) is a stock...
Analysartikel • Sep 05

C4 Therapeutics, Inc. (NASDAQ:CCCC) Held Back By Insufficient Growth Even After Shares Climb 33%

Despite an already strong run, C4 Therapeutics, Inc. ( NASDAQ:CCCC ) shares have been powering on, with a gain of 33...
Analysartikel • Jul 11

C4 Therapeutics, Inc. (NASDAQ:CCCC) Surges 27% Yet Its Low P/S Is No Reason For Excitement

C4 Therapeutics, Inc. ( NASDAQ:CCCC ) shares have continued their recent momentum with a 27% gain in the last month...
Analysartikel • Jun 20

We Think C4 Therapeutics (NASDAQ:CCCC) Needs To Drive Business Growth Carefully

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...
Analysartikel • Apr 18

Investors Don't See Light At End Of C4 Therapeutics, Inc.'s (NASDAQ:CCCC) Tunnel And Push Stock Down 40%

Unfortunately for some shareholders, the C4 Therapeutics, Inc. ( NASDAQ:CCCC ) share price has dived 40% in the last...
Seeking Alpha • Mar 10

C4 Therapeutics: Getting Too Cheap To Ignore, But There's Still A Lot Of Risk Here

Summary C4 Therapeutics' pipeline, including cemsidomide and CFT1946, shows early promise but faces significant safety concerns and long timelines for definitive data readouts. Financially, CCCC has sufficient cash to fund operations into 2027, reducing immediate dilution risk, but high cash burn remains a concern. Market valuation has dropped significantly, aligning more closely with their early-stage clinical status, reducing overvaluation risk. Despite potential in protein degraders, the current "Hold" sentiment is maintained due to early-stage data and lack of near-term catalysts. Read the full article on Seeking Alpha
Analysartikel • Mar 04

C4 Therapeutics, Inc. (NASDAQ:CCCC) Looks Inexpensive After Falling 31% But Perhaps Not Attractive Enough

To the annoyance of some shareholders, C4 Therapeutics, Inc. ( NASDAQ:CCCC ) shares are down a considerable 31% in the...
Analysartikel • Nov 15

C4 Therapeutics, Inc.'s (NASDAQ:CCCC) 33% Share Price Plunge Could Signal Some Risk

C4 Therapeutics, Inc. ( NASDAQ:CCCC ) shareholders won't be pleased to see that the share price has had a very rough...
Seeking Alpha • Nov 06

C4 Therapeutics: Holding Fast To A Generous Valuation Heading Into An Important ASH Readout

Summary C4 Therapeutics has a promising pipeline, including cemsidomide for blood cancer and CFT1946 for solid tumors, but definitive data is still far off. Financially stable with $59.6M in cash and $196M in marketable securities, CCCC has a cash runway of 11-12 quarters, funding operations through 2025. Strengths include controlled costs and no imminent dilution risk, but the long wait for significant data readouts poses a risk for investors. Maintain a "Hold" rating; worth watching for patient, risk-tolerant investors, but not advisable to jump in headfirst just yet. Read the full article on Seeking Alpha
Analysartikel • Oct 02

We're Not Very Worried About C4 Therapeutics' (NASDAQ:CCCC) Cash Burn Rate

There's no doubt that money can be made by owning shares of unprofitable businesses. Indeed, C4 Therapeutics...
Analysartikel • Aug 09

Analysts' Revenue Estimates For C4 Therapeutics, Inc. (NASDAQ:CCCC) Are Surging Higher

C4 Therapeutics, Inc. ( NASDAQ:CCCC ) shareholders will have a reason to smile today, with the analysts making...
Analysartikel • Aug 03

C4 Therapeutics, Inc.'s (NASDAQ:CCCC) 41% Share Price Surge Not Quite Adding Up

Those holding C4 Therapeutics, Inc. ( NASDAQ:CCCC ) shares would be relieved that the share price has rebounded 41% in...
Analysartikel • May 12

Analysts Just Published A Bright New Outlook For C4 Therapeutics, Inc.'s (NASDAQ:CCCC)

C4 Therapeutics, Inc. ( NASDAQ:CCCC ) shareholders will have a reason to smile today, with the analysts making...
Seeking Alpha • Mar 01

C4 Therapeutics' TORPEDO Platform Is Promising, But Its Valuation Remains Stretched

Summary C4 Therapeutics is developing targeted protein degraders for the treatment of various diseases, including cancer. The company's TORPEDO platform allows for the design of molecules that can break down disease-causing proteins. C4 Therapeutics has a partnership with Merck and is currently in Phase 1 clinical trials for its drug candidates. The company's current valuation appears high compared to sector peers, leading to a "hold" rating. Read the full article on Seeking Alpha
Analysartikel • Feb 29

Party Time: Brokers Just Made Major Increases To Their C4 Therapeutics, Inc. (NASDAQ:CCCC) Earnings Forecasts

Shareholders in C4 Therapeutics, Inc. ( NASDAQ:CCCC ) may be thrilled to learn that the analysts have just delivered a...
Analysartikel • Feb 24

C4 Therapeutics, Inc. (NASDAQ:CCCC) Reported Earnings Last Week And Analysts Are Already Upgrading Their Estimates

It's been a pretty great week for C4 Therapeutics, Inc. ( NASDAQ:CCCC ) shareholders, with its shares surging 13% to...
Analysartikel • Nov 03

New Forecasts: Here's What Analysts Think The Future Holds For C4 Therapeutics, Inc. (NASDAQ:CCCC)

C4 Therapeutics, Inc. ( NASDAQ:CCCC ) shareholders will have a reason to smile today, with the analysts making...

Analys av ersättningar till VD

Hur har Andrew Hirsch:s ersättning förändrats jämfört med C4 Therapeutics:s resultat?
DatumTotal ersättningLönFöretagets resultat
Mar 31 2026n/an/a

-US$104m

Dec 31 2025US$3mUS$695k

-US$105m

Sep 30 2025n/an/a

-US$119m

Jun 30 2025n/an/a

-US$112m

Mar 31 2025n/an/a

-US$103m

Dec 31 2024US$5mUS$665k

-US$105m

Sep 30 2024n/an/a

-US$105m

Jun 30 2024n/an/a

-US$108m

Mar 31 2024n/an/a

-US$126m

Dec 31 2023US$4mUS$639k

-US$132m

Sep 30 2023n/an/a

-US$135m

Jun 30 2023n/an/a

-US$140m

Mar 31 2023n/an/a

-US$131m

Dec 31 2022US$3mUS$614k

-US$128m

Sep 30 2022n/an/a

-US$107m

Jun 30 2022n/an/a

-US$99m

Mar 31 2022n/an/a

-US$95m

Dec 31 2021US$952kUS$580k

-US$84m

Sep 30 2021n/an/a

-US$80m

Jun 30 2021n/an/a

-US$82m

Mar 31 2021n/an/a

-US$73m

Dec 31 2020US$21mUS$168k

-US$66m

Ersättning vs marknad: Andrew s total kompensation ($USD 2.94M ) är ungefär genomsnittet för företag av liknande storlek på US marknaden ($USD 2.63M ).

Ersättning vs inkomst: Ersättningen från Andrew har varit i linje med företagets resultat under det senaste året.

VD OCH KONCERNCHEF

Andrew Hirsch (55 yo)

5.8yrs
Anställning
US$2,940,975
Kompensation

Mr. Andrew J. Hirsch, M.B.A., is Independent Director of Akamis Bio Limited from August 2025. He is the President of C4 Therapeutics, Inc since September 14, 2020 and has been its Chief Executive Officer s...

Ledningsgrupp

NamnPositionAnställningKompensationÄgarskap
Andrew Hirsch
CEO, President & Director5.8yrsUS$2.94m0.12%
$ 485.8k
Kenneth Anderson
Co-Founderno dataUS$85.50k0.32%
$ 1.3m
Kendra Adams
Principal Accounting Officer2.8yrsUS$1.48m0.041%
$ 162.3k
Leonard M. Reyno
Chief Medical Officer2.9yrsUS$1.64m0.023%
$ 91.5k
Nathanael Gray
Co-Founder & Member of Scientific Advisory Boardno datainga uppgifteringa uppgifter
Paige Mahaney
Chief Scientific Officer1.7yrsinga uppgifter0.016%
$ 65.2k
Courtney Solberg
Senior Manager of Investor Relationsno datainga uppgifteringa uppgifter
Kelly Schick
Chief People Officer5.4yrsinga uppgifter0.035%
$ 139.6k
Isabel Chiu
Senior Vice President of Strategic Alliances & Business Development10.3yrsinga uppgifteringa uppgifter
Christopher Nasveschuk
Senior Vice President of Chemistry5.4yrsinga uppgifteringa uppgifter
Roy Pollock
Senior Vice President of Biological Sciences7.3yrsinga uppgifteringa uppgifter
Mayra Reyes-Armour
Senior Vice President of Technical Operations5.4yrsinga uppgifteringa uppgifter
5.4yrs
Genomsnittlig anställningstid
55.5yo
Genomsnittlig ålder

Erfaren ledning: CCCC s ledningsgrupp är erfaren och erfaren ( 5.4 års genomsnittlig anställning).

Styrelseledamöter

NamnPositionAnställningKompensationÄgarskap
Andrew Hirsch
CEO, President & Director5.7yrsUS$2.94m0.12%
$ 485.8k
Kenneth Anderson
Co-Founder10.5yrsUS$85.50k0.32%
$ 1.3m
Nathanael Gray
Co-Founder & Member of Scientific Advisory Board9.6yrsinga uppgifteringa uppgifter
Christopher Bowden
Member of Clinical Advisory Boardno datainga uppgifteringa uppgifter
Steven Hoerter
Independent Director1.6yrsUS$90.31kinga uppgifter
Christopher Kirk
Member of Scientific Advisory Board9.6yrsinga uppgifteringa uppgifter
Ross Levine
Member of Scientific Advisory Board8.9yrsinga uppgifteringa uppgifter
Ronald H. Cooper
Independent Chairman2yrsUS$119.25k0%
$ 0
Ryan Corcoran
Member of Scientific Advisory Board6.8yrsinga uppgifteringa uppgifter
Scott Armstrong
Member of Scientific Advisory Board8.9yrsinga uppgifteringa uppgifter
Utpal Koppikar
Independent Director4.3yrsUS$100.50k0.0051%
$ 20.3k
Beni Wolf
Member of Clinical Advisory Boardno datainga uppgifteringa uppgifter
7.8yrs
Genomsnittlig anställningstid
55yo
Genomsnittlig ålder

Erfaren styrelse: CCCC s styrelse anses vara erfaren ( 7.8 års genomsnittlig mandatperiod).

Företagsanalys och finansiella data Status

UppgifterSenast uppdaterad (UTC-tid)
Analys av företag2026/06/10 23:54
Aktiekurs vid dagens slut2026/06/10 00:00
Intäkter2026/03/31
Årlig intjäning2025/12/31

Datakällor

Den data som används i vår företagsanalys kommer från S&P Global Market Intelligence LLC. Följande data används i vår analysmodell för att generera denna rapport. Data är normaliserade vilket kan medföra en fördröjning från det att källan är tillgänglig.

PaketUppgifterTidsramExempel US-källa
Företagets finansiella ställning10 år
  • Resultaträkning
  • Kassaflödesanalys
  • Balansräkning
Analytikernas konsensusuppskattningar+3 år
  • Prognos för finansiella poster
  • Analytikernas prismål
Marknadspriser30 år
  • Aktiekurser
  • Utdelningar, splittar och åtgärder
Ägarskap10 år
  • Största aktieägare
  • Insiderhandel
Förvaltning10 år
  • Ledningsgrupp
  • Styrelse och verkställande direktörer
Viktiga utvecklingstendenser10 år
  • Företagsmeddelanden

* Exempel för amerikanska värdepapper, för icke-amerikanska värdepapper används motsvarande regelverk och källor.

Om inget annat anges är all finansiell data baserad på en årsperiod men uppdateras kvartalsvis. Detta kallas data för efterföljande tolv månader (TTM) eller senaste tolv månader (LTM). Lär dig mer om detta.

Analysmodell och snöflinga

Detaljer om analysmodellen som användes för att skapa den här rapporten finns på vår Github-sida, vi har också guider om hur du använder våra rapporter och tutorials på Youtube.

Lär dig mer om det team i världsklass som utformade och byggde analysmodellen Simply Wall St.

Industri- och sektormått

Våra bransch- och sektionsmått beräknas var sjätte timme av Simply Wall St, detaljer om vår process finns tillgängliga på Github.

Källor för analytiker

C4 Therapeutics, Inc. bevakas av 15 analytiker. 6 av dessa analytiker lämnade de uppskattningar av intäkter eller resultat som användes som indata till vår rapport. Analytikernas inskickade estimat uppdateras löpande under dagen.

AnalytikerInstitution
Etzer DaroutBarclays
Chi Meng FongBofA Global Research
Leah Rush CannBrookline Capital Markets